Anadys' HCV drug gets FDA fast-track status

8 December 2008

The USA's Anadys Pharmaceuticals has been granted fast-track designation for its drug candidate ANA598 for chronic hepatitis C virus infection by the Food and Drug Administration.

The investigational hepatitis C non-nucleoside polymerase inhibitor is in a Phase Ib study currently enrolling chronic HCV patients.

The designation is intended to facilitate a drug's movement through the approval process thanks to measures such as timely review of protocols and frequent dialog with officials from the FDA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight